TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10194143

Group type: EXPERIMENTAL
Intervention: 200 micrograms fenoterol‐80 micrograms ipratropium bromide (four puffs) from a metered‐dose inhaler (MDI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.25 mg fenoterol‐500 micrograms ipratropium bromide in 5 ml saline from a nebulizer (NEB)
Number of subjects: 18
Study: 7779724

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 220

Group type: COMPARATOR
Intervention: CMF/EV (epirubicin, vincristine)
Number of subjects: 220
Study: 2181040

Group type: EXPERIMENTAL
Intervention: Various combinations of existing antileprosy drugs administered for 5 years to new untreated patients (Group I) and relapsed patients (Group II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine (even in low doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidrug regimen effective against both new and relapsed cases of lepromatous leprosy
Number of subjects: 0
Study: 386912

Group type: EXPERIMENTAL
Intervention: ephedrine + theophylline + hydroxyzine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ephedrine + theophylline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ephedrine + hydroxyzine
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 31253441

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 4983

Group type: EXPERIMENTAL
Intervention: Subgroup analysis (baseline Lp(a) ≥50 mg/dL)
Number of subjects: 4983
Study: 27392954

Group type: EXPERIMENTAL
Intervention: Cadmium (Cd) exposure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Molybdenum (HMo) exposure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Molybdenum (HMo) + Cadmium (Cd) exposure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no exposure)
Number of subjects: 120
Study: 27760066

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 24210570

Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: alfuzosin 10 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study: 21960156

Group type: EXPERIMENTAL
Intervention: 150 mg levobupivacaine in 60 mL 0.9% saline
Number of subjects: 91

Group type: COMPARATOR
Intervention: 60 mL 0.9% saline (placebo)
Number of subjects: 91
Study: 18996767

Group type: EXPERIMENTAL
Intervention: 120-s vagal blocking algorithm
Number of subjects: 27

Group type: COMPARATOR
Intervention: First-generation device with variable algorithm durations
Number of subjects: 27
Study: 17466722

Group type: EXPERIMENTAL
Intervention: Mirror therapy (30 minutes per day, 5 days a week for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 40
Study: 15860867

Group type: EXPERIMENTAL
Intervention: Hyperthermia (HT) combined with radiotherapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: No additional Hyperthermia (no-HT)
Number of subjects: 122
Study: 12475834

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fluticasone propionate 2000 microg/d
Number of subjects: 36
Study: 9787543

Group type: EXPERIMENTAL
Intervention: Antimicrobial oral rinse (0.12 percent chlorhexidine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No rinse
Number of subjects: 0
Study: 8584299

Group type: EXPERIMENTAL
Intervention: RGO‐II hybrid orthosis
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training programme
Number of subjects: 26
Study: 29433063

Group type: EXPERIMENTAL
Intervention: SSRIs and tandospirone
Number of subjects: 245

Group type: COMPARATOR
Intervention: SSRIs alone
Number of subjects: 245
Study: 28767524

Group type: EXPERIMENTAL
Intervention: Endurance exercise (60 min of treadmill running at 70% V˙O2peak)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Rest (no exercise)
Number of subjects: 7
Study: 26233628

Group type: EXPERIMENTAL
Intervention: Cataract surgery with blue-blocking intraocular lens (IOL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cataract surgery with neutral intraocular lens (IOL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 76
Study: 24216040

Group type: EXPERIMENTAL
Intervention: Antenatal education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antenatal education programme (Control)
Number of subjects: 0
Study: 21345770

Group type: EXPERIMENTAL
Intervention: Intraoperative cerebral regional oxygen saturation (rSO2) monitoring with active display (n = 28)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (blinded rSO2 monitoring, n = 29)
Number of subjects: 57
Study: 19855209

Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (retrospectively identified subjects)
Number of subjects: 0
Study: 16970227

Group type: EXPERIMENTAL
Intervention: Surgery in July and August
Number of subjects: 737

Group type: COMPARATOR
Intervention: Surgery during the rest of the year (September to June)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: All shunt procedures
Number of subjects: 737
Study: 15682349

Group type: EXPERIMENTAL
Intervention: Abacavir plus lamivudine (ABC+3TC)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Didanosine plus stavudine (ddI+d4T)
Number of subjects: 182
Study: 11737740

Group type: EXPERIMENTAL
Intervention: Standard dose nebulized albuterol therapy (0.15 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low dose nebulized albuterol (0.075 mg/kg) plus nebulized ipratropium bromide therapy (250 microg/dose)
Number of subjects: 43
Study: 9422890

Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bupivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ropivacaine and Bupivacaine
Number of subjects: 2
Study: 12959320

Group type: EXPERIMENTAL
Intervention: Minaprine 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Amitriptyline 25 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2827471

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg BID)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Enalapril plus sulindac (200 mg BID)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Enalapril plus indomethacin (50 mg BID)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 29
Study: 28082323

Group type: EXPERIMENTAL
Intervention: Second generation ENDS vape pen cue
Number of subjects: 108

Group type: COMPARATOR
Intervention: Traditional combustible cigarette smoking cue
Number of subjects: 108
Study: 27483312

Group type: EXPERIMENTAL
Intervention: Diet score assessing adherence to dietary recommendations
Number of subjects: 472
Study: 25015066

Group type: EXPERIMENTAL
Intervention: Late remote ischemic preconditioning (L‐RIPC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (uninflated cuff)
Number of subjects: 200
Study: 23194941

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Percutaneous transluminal balloon angioplasty (PTA)
Number of subjects: 200
Study: 21095266

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17971112

Group type: EXPERIMENTAL
Intervention: MOD preparation restored with composite resin (Z‐250, 3M ESPE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MOD preparation and endodontic treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MOD preparation, endodontic treatment, and composite resin restoration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intact teeth (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MOD preparation
Number of subjects: 50
Study: 15957693

Group type: EXPERIMENTAL
Intervention: 9.0 mg glucose-free bupivacaine with added fentanyl 20 microg (group BF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 11.0 mg glucose-free bupivacaine alone (group B)
Number of subjects: 40
Study: 12902533

Group type: EXPERIMENTAL
Intervention: Exercise (EX) group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (CO) group
Number of subjects: 31
Study: 10367599

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study: 7564346

Group type: EXPERIMENTAL
Intervention: UP269-6 (doses ranging from 5 to 180 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enalapril (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UP269-6 (20 mg and 40 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UP269-6
Number of subjects: 16
Study: 1767900

Group type: EXPERIMENTAL
Intervention: Thick layer of lignocaine-prilocaine cream (2.0 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thin layer of lignocaine-prilocaine cream (0.5 ml)
Number of subjects: 100
Study: 6951009

Group type: EXPERIMENTAL
Intervention: High-calorie dietary supplement providing a minimum of 50% of energy requirements
Number of subjects: 24

Group type: COMPARATOR
Intervention: Blenderized foods only (Control)
Number of subjects: 24
Study: 30638880

Group type: EXPERIMENTAL
Intervention: mHealth intervention via mobile Jump2Health website, Facebook posts, and text messages
Number of subjects: 30
Study: 28411244

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DESs) with paclitaxel
Number of subjects: 139

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty with bailout Bare Metal Stent (PTA-BMS)
Number of subjects: 139
Study: 27143273

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 10
Study: 24778230

Group type: EXPERIMENTAL
Intervention: Early success bestowed upon arbitrarily selected recipients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of nonrecipients
Number of subjects: 0
Study: 22433279

Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg orally twice daily
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 19727537

Group type: EXPERIMENTAL
Intervention: Trospium ER 60 mg once daily for 12 weeks
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study: 17499082

Group type: EXPERIMENTAL
Intervention: Emotional Expression (EE)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Insight and Cognitive Assimilation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 82
Study: 15562127

Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet
Number of subjects: 39
Study: 11168503

Group type: COMPARATOR
Intervention: MP/IFN-alpha
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: VBMCP/IFN-alpha
Number of subjects: 89
Study: 9624241

Group type: EXPERIMENTAL
Intervention: Lung cancer patients with microalbuminuria
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lung cancer patients without microalbuminuria
Number of subjects: 102

Group type: COMPARATOR
Intervention: Controls (benign lung disorders)
Number of subjects: 102
Study: 7875148

Group type: EXPERIMENTAL
Intervention: GM‐CSF, 5 micrograms/kg daily (intravenously or subcutaneously) for ten days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3340659

Group type: EXPERIMENTAL
Intervention: Orthoranger
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard goniometer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both instruments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orthoranger vs. manual goniometer
Number of subjects: 20
Study: 31391027

Group type: EXPERIMENTAL
Intervention: Active Attention Bias Modification Training (ABMT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control Attention Bias Modification Training (ABMT)
Number of subjects: 120
Study: 27943031

Group type: EXPERIMENTAL
Intervention: Living in 2 Worlds (L2W)
Number of subjects: 107

Group type: COMPARATOR
Intervention: kiR (control)
Number of subjects: 107
Study: 25993051

Group type: EXPERIMENTAL
Intervention: Intervention to promote the adoption of sun-safety policies
Number of subjects: 98
Study: 23361871

Group type: EXPERIMENTAL
Intervention: Bosentan for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no medication for first 3 months, then bosentan for 6 months)
Number of subjects: 42
Study: 21382132

Group type: EXPERIMENTAL
Intervention: SFC50/250/MF100
Number of subjects: 36

Group type: COMPARATOR
Intervention: SFC50/500
Number of subjects: 36
Study: 19565135

Group type: EXPERIMENTAL
Intervention: Domiciliary program of inspiratory muscle training for at least 2 weeks using a device with a load corresponding to 40% of the maximum inspiratory pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: General advice without inspiratory muscle training
Number of subjects: 30
Study: 17894257

Group type: EXPERIMENTAL
Intervention: Treatment participants received a series of mailed materials and two educational calls over 6 months.
Number of subjects: 2024

Group type: COMPARATOR
Intervention: Control group received a mailed pamphlet.
Number of subjects: 2024
Study: 14988574

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (not specified in detail)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Current standards of care (control group, not specified in detail)
Number of subjects: 58
Study: 12624706

Group type: EXPERIMENTAL
Intervention: Jogging on a treadmill for 30 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cycling on a bicycle ergometer for 30 min
Number of subjects: 20
Study: 9849179

Group type: EXPERIMENTAL
Intervention: Increased oral fluid intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High osmolarity liquid intake
Number of subjects: 0
Study: 7852747

Group type: EXPERIMENTAL
Intervention: Omacor (85% n‐3 fatty acid concentrate)
Number of subjects: 43

Group type: COMPARATOR
Intervention: corn oil (4 capsules of 1g/day)
Number of subjects: 43
Study: 2767502

Group type: EXPERIMENTAL
Intervention: Early dinner (dinner at 6 pm)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Late dinner (dinner at 9 pm)
Number of subjects: 23
Study: 965543

Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonsupervised training
Number of subjects: 18

Group type: COMPARATOR
Intervention: No training control
Number of subjects: 18
Study: 30240132

Group type: COMPARATOR
Intervention: CSL112 2 g
Number of subjects: 32

Group type: COMPARATOR
Intervention: CSL112 6 g
Number of subjects: 32
Study: 28790038

Group type: EXPERIMENTAL
Intervention: ParticiPAte CP (participation focused therapy)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist usual care
Number of subjects: 36
Study: 24995862

Group type: EXPERIMENTAL
Intervention: Ultrasonic piezoelectric device, Perio 100% setting, level 8 (P100)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasonic piezoelectric device, Surg 50% setting, level 1 (S50)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gracey curettes (CUR)
Number of subjects: 30
Study: 22276690

Group type: EXPERIMENTAL
Intervention: Immediate placement of wide-diameter implants in fresh molar extraction sockets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed placement of wide-diameter implants in healed sites
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (immediate and delayed placement)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Immediately placed implants
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed placed implants
Number of subjects: 24
Study: 21498904

Group type: EXPERIMENTAL
Intervention: Cognitive intervention group (IG) receiving weekly sessions of group‐based multicomponent cognitive intervention.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Active control group (CG) receiving pencil‐paper exercises for self‐study.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cognitive intervention group (IG) for aMCI.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cognitive intervention group (IG) for AD.
Number of subjects: 39
Study: 18574688

Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Homozygote mutants in GSTP1
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Three‐way combination of GSTP1 105AA/AG and null genotypes for both GSTM1 and GSTT1
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Family history of breast cancer
Number of subjects: 413

Group type: COMPARATOR
Intervention: GSTT1 null genotype
Number of subjects: 413
Study: 17194949

Group type: EXPERIMENTAL
Intervention: Preclinic appointment telephone contact (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No preclinic appointment telephone contact (group B)
Number of subjects: 100
Study: 15165653

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 601
Study: 11922398

Group type: EXPERIMENTAL
Intervention: Troxerutin 150 mg and carbazochrome 1.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9517631

Group type: EXPERIMENTAL
Intervention: Foscarnet 90 mg/kg b.i.d. for 21 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ganciclovir 5 mg/kg b.i.d. for 21 days
Number of subjects: 23
Study: 8299789

Group type: EXPERIMENTAL
Intervention: CC-stimulated, hCG-timed IUI
Number of subjects: 56

Group type: COMPARATOR
Intervention: LH-timed IUI
Number of subjects: 56
Study: 2680583

Group type: EXPERIMENTAL
Intervention: 10 mg protriptyline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20 mg protriptyline
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 786204

Group type: EXPERIMENTAL
Intervention: Imipramine 300 mg daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Imipramine 150 mg daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Deluded depressives
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nondeluded depressives
Number of subjects: 51
Study: 31063575

Group type: EXPERIMENTAL
Intervention: Aclidinium (400 μg twice daily)
Number of subjects: 3630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3630
Study: 28776629

Group type: EXPERIMENTAL
Intervention: No valve cast
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Univalve cast
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bivalve cast
Number of subjects: 60
Study: 25128968

Group type: EXPERIMENTAL
Intervention: Hamstring graft (HS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patellar tendon (BTB)
Number of subjects: 150
Study: 23461008

Group type: EXPERIMENTAL
Intervention: mexidol (2-ethyl-6-methyl-3-oxypyridine succinate)
Number of subjects: 62
Study: 21223352

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sponge toothette
Number of subjects: 46
Study: 19918595

Group type: EXPERIMENTAL
Intervention: Local antibiotics (two groups with proven efficacy)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 3% hydrogen peroxide (H2O2)
Number of subjects: 57
Study: 16500952

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia (XE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Total i.v. anaesthesia (TIVA)
Number of subjects: 44
Study: 17261876

Group type: EXPERIMENTAL
Intervention: Biphasic intermittent positive airway pressure (BIPAP)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 56
Study: 12801946

Group type: EXPERIMENTAL
Intervention: Apple juice (pH 3.0)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acidified Ensure (pH 3.0)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Neutral Ensure (pH 7.0)
Number of subjects: 11
Study: 10618679

Group type: EXPERIMENTAL
Intervention: M235T genotype
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: G(-6)A genotype
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Agreement of genotypes
Number of subjects: 128
Study: 7491889

Group type: EXPERIMENTAL
Intervention: Diet 2 (3.4% fiber, 15.6% lipid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diet 1 (6.4% fiber, 13.1% lipid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diet 3 (4.4% fiber, 14.5% lipid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diet 2 vs Diet 1
Number of subjects: 18
Study: 1788456

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Xipamide
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 54
Study: 7338581

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study: 28643063

Group type: EXPERIMENTAL
Intervention: One-step nucleic acid (OSNA) analysis of lymph nodes identified by indocyanine green (ICG) fluorescence during surgery.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ICG fluorescence identification of lymph nodes.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: OSNA analysis of ICG-labelled nodes compared to final histological nodal stage.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Conventional histology and OSNA assessment of fresh lymph nodes.
Number of subjects: 16
Study: 27515481

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BRS) without postdilatation
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BRS) with postdilatation
Number of subjects: 215

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BRS)
Number of subjects: 215
Study: 24878273

Group type: EXPERIMENTAL
Intervention: Minimally invasive unilateral laminectomy for bilateral decompression (ULBD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Open laminectomy
Number of subjects: 54